Clinical trial
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver…
NCT00006006 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00006006 |
|---|---|
| Title | Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed |
| Official title | Thalidomide for Unresectable Hepatocellular Cancer With Optional Interferon Alpha-2a Upon Disease Progression |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, thalidomide |
| Enrollment | 38 |
| Start date | Aug 1, 2000 |
| Primary completion | Mar 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: